SUBOXONE Drug Patent Profile

When do Suboxone patents expire, and when can generic versions of Suboxone launch?

Suboxone is a drug marketed by Indivior and is included in two NDAs. There are three patents protecting this drug and three Paragraph IV challenges.

This drug has thirty-two patent family members in twenty-four countries.

The generic ingredient in SUBOXONE is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Suboxone

A generic version of SUBOXONE was approved as buprenorphine hydrochloride; naloxone hydrochloride by ACTAVIS ELIZABETH on February 22^nd, 2013.

Summary for SUBOXONE

International Patents:	32
US Patents:	3
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	30
Clinical Trials:	100
Drug Prices:	Drug price information for SUBOXONE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SUBOXONE
What excipients (inactive ingredients) are in SUBOXONE?	SUBOXONE excipients list
DailyMed Link:	SUBOXONE at DailyMed

See drug prices for SUBOXONE

See drug sales revenues for SUBOXONE

Recent Clinical Trials for SUBOXONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Indivior Inc.	PHASE2
National Institute on Drug Abuse (NIDA)	PHASE4
Erin Winstanley	PHASE4

See all SUBOXONE clinical trials

Pharmacology for SUBOXONE

Drug Class	Opioid Antagonist Partial Opioid Agonist
Mechanism of Action	Opioid Antagonists Partial Opioid Agonists

Paragraph IV (Patent) Challenges for SUBOXONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SUBOXONE	Sublingual Film	buprenorphine hydrochloride; naloxone hydrochloride	12 mg/3 mg	022410	1	2013-05-14
SUBOXONE	Sublingual Film	buprenorphine hydrochloride; naloxone hydrochloride	2 mg/0.5 mg and 8 mg/2 mg	022410	1	2012-10-15
SUBOXONE	for Injection	buprenorphine hydrochloride; naloxone hydrochloride	500 mg/vial	020733	2	2009-01-26

US Patents and Regulatory Information for SUBOXONE

SUBOXONE is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-001	Aug 30, 2010	AB	RX	Yes	No	9,687,454		Y
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-002	Aug 30, 2010	AB	RX	Yes	No	8,475,832		Y
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-003	Aug 10, 2012	AB	RX	Yes	No	9,687,454		Y

Expired US Patents for SUBOXONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-002	Aug 30, 2010	9,855,221
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-004	Aug 10, 2012	9,855,221
Indivior	SUBOXONE	buprenorphine hydrochloride; naloxone hydrochloride	FILM;BUCCAL, SUBLINGUAL	022410-004	Aug 10, 2012	8,017,150

International Patents for SUBOXONE

When does loss-of-exclusivity occur for SUBOXONE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Denmark

European Patent Office

Hong Kong

Israel

Japan

Malaysia

Mexico

New Zealand

Peru

Russian Federation

Singapore

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SUBOXONE around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	077803	COMPOSICIONES DE PELICULA SUBLINGUALES Y BUCALES. PROCESO. METODO DE TRATAMIENTO
Austria	536868
Austria	536869

Last updated: July 20, 2026

Suboxone (buprenorphine/naloxone) market dynamics and financial trajectory

Executive summary: Suboxone has been a long-running, high-liquidity brand in opioid use disorder (OUD). Its market trajectory is shaped by (1) steady OUD prevalence and ongoing opioid-treatment demand, (2) loss of meaningful exclusivity for key single-ingredient and combination constructs while maintaining brand differentiation, (3) payer and formulary decisions across buprenorphine products, (4) access and diversion-control considerations, and (5) periodic competitive pressure from generic buprenorphine/naloxone products and newer branded delivery options in the OUD portfolio. Financial performance depends primarily on U.S. unit share across tablet/film presentations, pharmacy benefit coverage for each strength, and the degree of generic penetration in each channel.

---

How has Suboxone performed financially since launch, and what drives revenue growth or decline?

Direct answer: Suboxone’s financial trajectory in the U.S. has been sustained by ongoing OUD demand and durable prescribing, but annual growth has generally flattened as generic buprenorphine/naloxone competition increased and as payers tightened formulary preferences. Revenue sensitivity concentrates in (a) prescription volume, (b) price and contract dynamics with PBMs, and (c) channel mix between retail and covered specialty networks that administer OUD therapies.

Key performance drivers that explain yearly swings

1. OUD treatment penetration and retention
   • Demand is anchored to the number of patients who receive maintenance therapy and stay on treatment. Discontinuation rates, adherence, and clinician prescribing patterns drive prescription counts.
2. Generic substitution and rebate economics
   • Generic buprenorphine/naloxone products compress net prices when formularies place them on preferred tiers.
3. Formulary placement by PBMs
   • Shifts across preferred/covered alternatives change net revenue per script.
4. Product presentation mix
   • Film vs tablet mix matters for patient preference, prescriber comfort, and dispensing behavior.
5. Regulatory and safety positioning
   • Changes in label language, REMS requirements, and safety communications can alter prescriber adoption, though Suboxone is an established therapy with stable core use.

---

What is Suboxone’s current market size and competitive share across buprenorphine/naloxone options?

Direct answer: Suboxone competes within the U.S. buprenorphine-based OUD class that includes generic buprenorphine/naloxone and other branded buprenorphine products. Competitive share is determined less by “class demand” and more by payer preference, patient adherence, and formulary tiering among buprenorphine/naloxone tablets and films.

Competitive set: how substitution typically plays out

• Primary substitutes
  • Generic buprenorphine/naloxone films and tablets.
  • Branded buprenorphine OUD products with different delivery systems and/or payer contracts.
• Why Suboxone can retain value even when generics exist
  • Brand recognition, prescriber inertia, patient familiarity.
  • Supply stability and presentation continuity.
  • Contracting and rebate strategies that keep Suboxone “covered” despite lower-cost alternatives.

Channel dynamics that influence net sales

• Retail pharmacy is usually the largest share driver for maintenance prescriptions.
• Patient assistance and payer rules affect persistence and can shift quarterly prescription volume.
• Institutional purchasing in certain settings may accelerate generic substitution.

---

When does Suboxone lose exclusivity, and how has that influenced generic entry risk?

Direct answer: Suboxone’s key market exclusivity has already expired, enabling generic versions. The generic-entry risk is therefore less about first generic entry timing and more about ongoing substitution into preferred formulary positions as manufacturing capacity expands and PBM contracts refresh.

What “exclusivity loss” means in practice for Suboxone

• Even with exclusivity largely exhausted, Suboxone revenue can persist due to contracting outcomes and patient continuity.
• The incremental risk is periodic: when PBM formularies change tiers, net sales can step down quickly even if total OUD prescriptions remain stable.

---

Which Suboxone competitors pressure unit share the most, and how does each affect net pricing?

Direct answer: Generic buprenorphine/naloxone products exert the most direct share and net price pressure because they are therapeutic equivalents with strong cost advantages. Branded competitors can pressure share when payers prefer them on preferred tiers, especially where dosing convenience and clinical pathways align.

Competitive impact by “type”

1. Generics (price and share)
   • Net price compression usually dominates financial impact.
   • PBM preferred-tier placement increases script migration.
2. Other branded buprenorphine options (tier dynamics)
   • Can move patients if payer coverage, co-pay structures, or clinician experience favors alternative products.
3. Delivery and adherence differentiation
   • Products that improve adherence or reduce dosing barriers can shift share away from daily maintenance regimens.

---

How do payer contracts and PBM formularies affect Suboxone’s net sales trajectory?

Direct answer: Suboxone’s net sales path is highly sensitive to the PBM formulary status of its specific strengths and dosage forms. Preferred placement supports script volume and mitigates net price declines; tier downgrades accelerate generic substitution.

Mechanics that drive quarter-to-quarter volatility

• Formulary tiering
  • Preferred tiers increase utilization and lower patient out-of-pocket costs.
• Rebate and contract renewal timing
  • Rebates can mask gross-to-net erosion until contract resets.
• Plan design changes
  • Narrow networks, prior authorization, step therapy, or co-pay management can change adherence and persistence.

---

What formulation, route, and dosage mix matters most for Suboxone’s financial performance?

Direct answer: Mix across Suboxone film and tablet strengths drives effective price and net revenue because payer coverage and patient preference vary by presentation. Changes in dispensing behavior and substitution patterns by dosage form influence revenue per prescription.

Revenue-relevant mix variables

• Strength distribution (higher vs lower strengths)
• Film vs tablet selection by prescriber preference and patient handling needs
• Generic substitution rates by presentation and state-level pharmacy dynamics

---

What role do opioid policy changes play in Suboxone demand, and how do they translate to revenue?

Direct answer: OUD policy affects access, prescribing, and persistence. In practice, changes that expand access to medication-assisted treatment increase the addressable patient pool, while restrictive policies can slow new starts and reduce continuity.

Policy levers that map to financial outcomes

• Expansion of office-based treatment capacity
• Telehealth rules for initiation and follow-up
• Limits and administrative burden for buprenorphine dispensing
• Coverage expansions or restrictions within Medicaid and commercial plans

---

What is Suboxone’s Orange Book and patent landscape relevance to market dynamics?

Direct answer: Suboxone’s practical market dynamics are dominated by generic competitive realities rather than brand exclusivity. The key financial impact comes from ongoing substitution and payer contracting after exclusivity expiration, not from preventing generic entry.

Why patent estate matters less than contracting now

• Once multiple equivalent generics are on market, brand economics pivot to net price, rebate structure, and formulary placement.
• Brand differentiation is anchored in clinician/patient workflow and supply reliability more than legal barriers.

---

How does Suboxone compare with other OUD branded therapies on competitive positioning?

Direct answer: In OUD, competing brands often compete through differentiated delivery systems, payer contracts, and adherence or convenience features. Suboxone’s position is strengthened by broad familiarity and established prescribing patterns, but it faces persistent generic cost pressure.

Suboxone vs. alternative branded pathways

• Oral daily maintenance products rely on patient adherence and refill continuity.
• Long-acting or convenience-oriented approaches can shift payer preference if they reduce utilization friction.
• Suboxone’s advantage remains breadth of clinical adoption and day-to-day dosing familiarity.

---

What generic entry risks still exist for Suboxone, and where can revenue be pressured next?

Direct answer: Even with generics available, the remaining revenue risks are “mechanical” rather than “legal”: formulary re-tiering, contract resets that reduce brand competitiveness, and shifts in PBM preferred status by strength or dosage form.

Where pressure typically reappears

• New PBM contract cycles
• Regional formulary updates
• Changes in step therapy or prior authorization rules
• Increased generic manufacturing supply that reduces list price and rebate leverage

---

How do manufacturing, supply constraints, and distribution affect Suboxone financial results?

Direct answer: OUD maintenance therapy requires steady supply. Supply interruptions can temporarily shift utilization to alternatives, with knock-on effects on patient persistence. When supply stabilizes, share can partially recover but not always fully.

Financial implications of supply events

• Short-term missed scripts during shortages
• Switching costs for patients and prescribers
• Long-term retention effects if patients settle on alternatives

---

What litigation or settlement dynamics typically influence Suboxone market outcomes?

Direct answer: For established brands like Suboxone, legal outcomes mostly affect timing of specific generic entries or prevent certain formulation or manufacturing workarounds. Once generics are broadly available, litigation impact becomes sporadic and contract-specific.

How legal events translate to revenue

• Entry timing of additional competitors can accelerate net price compression.
• Settlement terms can define “launch windows” that change quarterly script migration.

---

Key Takeaways

• Suboxone’s financial trajectory is driven primarily by OUD demand and payer contracting, not by exclusivity, which has largely run its course.
• Generic buprenorphine/naloxone products exert the strongest persistent pressure on net pricing and share through formulary substitution.
• The most actionable market levers are PBM tier status, strength and dosage-form coverage, contract and rebate reset timing, and the degree of switch from brand to equivalent generics.
• Residual risks are mostly periodic: contract cycles, policy changes affecting access, and supply stability that preserves patient persistence.

---

FAQs

1. What drives Suboxone film vs tablet utilization differences across insurance plans?
2. How quickly do formulary tier changes for buprenorphine/naloxone affect Suboxone net sales?
3. What patient persistence factors most influence long-term Suboxone prescription volumes?
4. How do PBM prior authorization and step therapy rules typically change substitution patterns within OUD maintenance therapy?
5. Which budget categories (Medicaid vs commercial) usually show the largest sensitivity to Suboxone pricing changes?

---

References (APA)

1. FDA Drug Labeling: SUBOXONE (buprenorphine and naloxone) prescribing information. U.S. Food and Drug Administration.
2. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
3. FDA Drug Shortages: Suboxone-related shortage notices (if any during the period of interest). U.S. Food and Drug Administration.
4. U.S. Drug Pricing and reimbursement reporting by CMS and PBM-related analyses (market access). Centers for Medicare & Medicaid Services.

DrugChatter Q&A for SUBOXONE

What medications can you not take with suboxone?
Suboxone generic availability?
Patent expiry suboxone australia?
Cost of suboxone treatment?
What company makes suboxone?